Huerta C, Rivero E, Rodríguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007;143(12):1559–65.

Article  PubMed  Google Scholar 

Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201.

Article  PubMed  Google Scholar 

Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633–6.

Article  CAS  PubMed  Google Scholar 

Eichenfield LF, Paller AS, Tom WL, Sugarman J, Hebert AA, Friedlander SF, et al. Pediatric psoriasis: evolving perspectives. Pediatr Dermatol. 2018;35(2):170–81.

Article  PubMed  Google Scholar 

Bilgic A, Bilgic Ö, Akış HK, Eskioğlu F, Kılıç EZ. Psychiatric symptoms and health-related quality of life in children and adolescents with psoriasis. Pediatr Dermatol. 2010;27(6):614–7.

Article  PubMed  Google Scholar 

De Jager MEA, De Jong E, Evers AWM, Van De Kerkhof PCM, Seyger MMB. The burden of childhood psoriasis. Pediatr Dermatol. 2011;28(6):736–7.

Article  PubMed  Google Scholar 

Seyhan M, Coşkun BK, Sağlam H, Ozcan H, Karincaoğlu Y. Psoriasis in childhood and adolescence: evaluation of demographic and clinical features. Pediatr Int. 2006;48(6):525–30.

Article  PubMed  Google Scholar 

Frangos JE, Kimball AB. Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses. Expert Opin Pharmacother. 2008;9(11):2001–7.

Article  CAS  PubMed  Google Scholar 

Brune A, Miller DW, Lin P, Cotrim-Russi D, Paller AS. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol. 2007;24(1):76–80.

Article  PubMed  Google Scholar 

de Jager ME, de Jong EM, van de Kerkhof PC, Seyger MM. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol. 2010;62(6):1013–30.

Article  PubMed  Google Scholar 

US FDA. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050777s018lbl.pdf. Accessed 3 Sep 2023.

US FDA. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021302s011lbl.pdf. Accessed 3 Sep 2023.

Seyger M, Abramovits W, Liljedahl M, Hoejen MN, Teng J. Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial. J Eur Acad Dermatol Venereol. 2020;34(9):2026–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

ClinicalTrials.gov. Plaque psoriasis study in pediatric subjects. 2023. https://clinicaltrials.gov/study/NCT02186665. Accessed 1 Aug 2023.

Kortuem KR, Davis MD, Witman PM, McEvoy MT, Farmer SA. Results of Goeckerman treatment for psoriasis in children: a 21-year retrospective review. Pediatr Dermatol. 2010;27(5):518–24.

Article  PubMed  Google Scholar 

Borska L, Andrys C, Krejsek J, Hamakova K, Kremlacek J, Ettler K, et al. Genotoxic hazard and cellular stress in pediatric patients treated for psoriasis with the Goeckerman regimen. Pediatr Dermatol. 2009;26(1):23–7.

Article  PubMed  Google Scholar 

Borska L, Smejkalova J, Cerna M, Hamakova K, Kucera I, Kremlacek J, et al. Urinary mutagenicity and genotoxic risk in children with psoriasis after therapeutic exposure to polycyclic aromatic hydrocarbons and ultraviolet radiation. Mutat Res. 2010;696(2):144–7.

Article  CAS  PubMed  Google Scholar 

Petersen B, Lebwohl M. Treating scalp psoriasis with calcipotriene/betamethasone dipropionate fixed-dose combination cutaneous foam: review of phase 2 data. J Drugs Dermatol. 2020;19(8):784–6.

Article  PubMed  Google Scholar 

Darley CR, Cunliffe WJ, Green CM, Hutchinson PE, Klaber MR, Downes N. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol. 1996;135(3):390–3.

Article  CAS  PubMed  Google Scholar 

Diluvio L, Campione E, Paternò EJ, Mordenti C, El Hachem M, Chimenti S. Childhood nail psoriasis: a useful treatment with tazarotene 0.05%. Pediatr Dermatol. 2007;24(3):332–3.

Article  PubMed  Google Scholar 

ClinicalTrials.gov. A safety and pharmacokinetics study of IDP-118 lotion in pediatric participants with plaque psoriasis. 2023. https://clinicaltrials.gov/ct2/show/NCT03988439. Accessed 1 Jun 2023.

Lebwohl MG, Sugarman JL, Gold LS, Pariser DM, Lin T, Pillai R, et al. Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;80(1):282–5.

Article  CAS  PubMed  Google Scholar 

Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432–70.

Article  PubMed  Google Scholar 

Koo J, Cuffie CA, Tanner DJ, Bressinck R, Cornell RC, DeVillez RL, et al. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther. 1998;20(2):283–91.

Article  CAS  PubMed  Google Scholar 

Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol. 2005;141(1):43–6.

Article  CAS  PubMed  Google Scholar 

Arcutis Biotherapeutics. FDA approves Arcutis’ ZORYVE™ (roflumilast) cream 0.3% for the treatment of plaque psoriasis in individuals age 12 and older. 2022. https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-psoriasis-in-individuals-age-12-and-older/. Accessed 25 Apr 2023.

Milakovic M, Gooderham MJ. Phosphodiesterase-4 inhibition in psoriasis. Psoriasis (Auckl). 2021;11:21–9.

PubMed  PubMed Central  Google Scholar 

Lé AM, Torres T. New topical therapies for psoriasis. Am J Clin Dermatol. 2022;23(1):13–24.

Article  PubMed  Google Scholar 

Lebwohl MG, Kircik LH, Moore AY, Stein-Gold L, Draelos ZD, Gooderham MJ, et al. Effect of roflumilast cream vs. vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials. JAMA. 2022;328(11):1073–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khosravi H, Siegel MP, Van Voorhees AS, Merola JF. Treatment of inverse/intertriginous psoriasis: updated guidelines from the Medical Board of the National Psoriasis Foundation. J Drugs Dermatol. 2017;16(8):760–6.

CAS  PubMed  Google Scholar 

Stein Gold L A-LJ, Draelos ZD, et al. Correlation of itch response to roflumilast cream with disease severity and patient-reported outcomes in patients with chronic plaque psoriasis. In: American Academy of Dermatology Annual Meeting; 2021; Virtual.

Thurston AW Jr, Osborne DW, Snyder S, Higham RC, Burnett P, Berk DR. Pharmacokinetics of roflumilast cream in chronic plaque psoriasis: fata from phase I to phase III studies. Am J Clin Dermatol. 2023;24(2):315–24.

Article  PubMed  Google Scholar 

ClinicalTrials.gov. Safety and efficacy of ARQ-154 foam in adolescent and adult subjects with scalp and body psoriasis. 2022. https://clinicaltrials.gov/study/NCT04128007. Accessed 1 Aug 2023.

Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49.

Article  CAS  PubMed  Google Scholar 

Lee EB, Lebwohl MG, Wu JJ. Treatment of psoriasis with crisaborole. J Dermatolog Treat. 2019;30(2):156–7.

Article  CAS  PubMed  Google Scholar 

Robbins AB, Gor A, Bui MR. Topical crisaborole: a potential treatment for recalcitrant palmoplantar psoriasis. JAMA Dermatol. 2018;154(9):1096–7.

Article  PubMed  Google Scholar 

Dong C, Virtucio C, Zemska O, Baltazar G, Zhou Y, Baia D, et al. Treatment of skin inflammation with benzoxaborole phosphodiesterase inhibitors: selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes. J Pharmacol Exp Ther. 2016;358(3):413–22.

Article  CAS  PubMed  Google Scholar 

Chung M, Yeroushalmi S, Hakimi M, Bartholomew E, Liao W, Bhutani T. A critical review of halobetasol propionate foam (005%) as a treatment option for adolescent plaque psoriasis. Expert Rev Clin Immunol. 2022;18(10):997–1003.

Article  CAS  PubMed  Google Scholar 

ClinicalTrials.gov. Adrenal suppression and absorption study of halobetasol propionate foam in subjects 12-17 with plaque psoriasis. 2022. https://clinicaltrials.gov/study/NCT03992261. Accessed 1 Aug 2023.

Jett JE, McLaughlin M, Lee MS, Parish LC, DuBois J, Raoof TJ, et al. Tapinarof cream 1% for extensive plaque psoriasis: a maximal use trial on safety, tolerability, and pharmacokinetics. Am J Clin Dermatol. 2022;23(1):83–91.

Article  PubMed  Google Scholar 

Lebwohl MG, Stein Gold L, Strober B, Papp KA, Armstrong AW, Bagel J, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219–29.

Article  CAS  PubMed  Google Scholar 

Strober B, Stein Gold L, Bissonnette R, Armstrong AW, Kircik L, Tyring SK, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;87(4):800–6.

Article  CAS  PubMed  Google Scholar 

Furue M. Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis. Int J Mol Sci. 2020;21(15):5382.

Article